Mr. Don Cilla reports

APPILI THERAPEUTICS PROVIDES UPDATE ON ARRANGEMENT WITH ADITXT, INC.

Aditxt Inc. has delivered notice purporting to terminate the arrangement agreement dated April 1, 2024, between Appili Therapeutics Inc., Aditxt and its wholly owned subsidiary Adivir Inc. (as amended on July 1, 2024, and further amended on July 17, 2024, and as further amended on Aug. 20, 2024, such termination to be effective as of May 31, 2025).

Under the arrangement agreement, the company is entitled to a termination fee in the amount of $1.25-million (U.S.) payable by Aditxt upon termination of the arrangement agreement in certain circumstances. This termination fee is to be reduced by certain amounts previously paid to the company by Aditxt to extend the outside date under the arrangement agreement. As of the date hereof, the amount of $1-million (U.S.) would be payable to Appili on account of the termination fee.

The foregoing summary of certain provisions of the arrangement is qualified in its entirety by the provisions of the arrangement agreement, a copy of which is available on SEDAR+.

About Appili Therapeutics Inc.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio driven and people focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili has a goal to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The company is currently advancing a diverse range of anti-infectives, including a Food and Drug Administration-approved ready-made suspension of metronidazole for the treatment of anti-microbial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical anti-parasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicentre of the global fight against infection.

We seek Safe Harbor.